Agile Therapeutics (AGRX) Given News Sentiment Rating of 0.16

Press coverage about Agile Therapeutics (NASDAQ:AGRX) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Agile Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 44.8654274634958 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news stories that may have effected Accern Sentiment Analysis’s analysis:

Shares of Agile Therapeutics (AGRX) traded up $0.07 during mid-day trading on Friday, hitting $3.54. The stock had a trading volume of 268,767 shares, compared to its average volume of 923,073. The company has a market cap of $123.46, a price-to-earnings ratio of -3.85 and a beta of 2.00. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.

Agile Therapeutics (NASDAQ:AGRX) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.03. research analysts forecast that Agile Therapeutics will post -0.97 EPS for the current fiscal year.

AGRX has been the topic of a number of recent research reports. HC Wainwright set a $8.00 price objective on Agile Therapeutics and gave the stock a “buy” rating in a report on Friday, December 22nd. Noble Financial reaffirmed a “buy” rating on shares of Agile Therapeutics in a report on Friday, December 22nd. Royal Bank of Canada reaffirmed a “buy” rating and issued a $10.00 price target on shares of Agile Therapeutics in a report on Wednesday, October 18th. Cantor Fitzgerald reiterated a “buy” rating and set a $8.00 price objective on shares of Agile Therapeutics in a research report on Monday, November 20th. Finally, Janney Montgomery Scott lowered Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $9.20.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/20/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-agile-therapeutics-agrx-stock-price.html.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Insider Buying and Selling by Quarter for Agile Therapeutics (NASDAQ:AGRX)

Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply